results presented warrant an expanded case-control study to determine the pathophysiological implications of DNA methylation for hyper-homocysteinemia.
Introduction
Despite considerable progress in candidate gene identification, only a small fraction of the overall genetic risk for complex disease (ie: coronary artery disease and stroke) can be explained by common variants described by genome-wide association studies (GWAS) [1, 2, 3] . Environmental factors conferring epigenetic changes provide an alternative mechanism to explain vascular disease susceptibility and progression [4] . Homocysteine (Hcy) is the demethylated form of methionine found in blood plasma as an S-linked protein mixed disulfide. Patients with hyperhomocysteinemia (HHcy) caused by genetic mutations are prone to systemic arterial damage and microvascular hemorrhage [5] . Meta-analyses show that moderate HHcy is a risk factor for premature stroke and coronary artery disease independent of smoking, total cholesterol and systolic blood pressure [6] . Hcy is an endogenous inhibitor of methyltransferases; with numerous in vitro experiments, animal models as well as human studies showing a link between elevated homocysteine and reduced genomic 5-methylcytosine (5mC; reviewed in [7] ). Loss of 5mC at LINE-1 elements is associated with elevated risk of ischemic heart disease and stroke implicating its importance in vascular health [8] . However, relatively little is known of the genomic methylation changes mediated by elevated Hcy. In this study, we examined the relationship between Abstract: Despite recent progress in screening for genetic causes of cardiovascular disease using genome-wide association studies, identifying causative polymorphisms has not met initial expectations. This has led to interest in exploring the contribution of non-genetic factors in disease etiology. Elevated plasma homocysteine is an independent risk factor for cardiovascular disease but the mechanism for increased risk remains poorly understood. This study evaluates the clinical applicability of screening for genome-wide CpG methylation differences using methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq). Peripheral blood genomic DNA methylation in 8 Singaporean-Chinese ischemic stroke patients (4 male, 4 female) was profiled. Differential methylation of genes implicated in hyperhomocysteinemia was observed in males correlating with homocysteine; namely CBS (cystathionine-beta-synthase) and MTHFR (methylenetetrahydrofolate reductase). In females, hypomethylation of the LDLR (low density lipoprotein receptor) and CELSR1 (cadherin, EGF LAG seven-pass G-type receptor 1) genes were observed in the hypertensive group (2 normal and 2 hypertensive individuals). While the number of clinical samples analysed is small, the findings of this evaluation suggest that MBD-seq is a suitable and sufficiently sensitive technology to determine methylation variability. The hypertension and plasma Hcy levels with genome-wide 5mC in a small group of ischemic stroke patients using methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq) [9] . To the best of our knowledge, this is the first description of genome-wide MBD-seq to determine genomic methylation changes associated with cardiovascular disease risk.
Materials and Methods

Subjects
The study was approved by the SingHealth Centralised Institutional Review Board, and informed consent was obtained from each subject at recruitment. A total of eight acute ischemic stroke patients attending the Neurology Department at Singapore General Hospital were recruited. The ages of patients ranged from 43 to 80 and their Hcy titers ranged from 7.3 to 19.8 μmol/L. Four patients had a history of hypertension (Table 1 ). All patients received brain imaging with computed tomography or MRI, imaging of extracranial carotid arteries with ultrasound, and imaging of intracranial carotid arteries with Transcranial Color-Coded Doppler with or without magnetic resonance angiography as previously reported [10] .
Homocysteine assay
Total Hcy was assayed by high performance liquid chromatography (HPLC) on the DxC 800 instrument (Beckman Coulter) using the Homocysteine Assay kit (Catch Inc.).
DNA isolation and methylcytosine quantification
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque PLUS density gradient centrifugation according to the manufacturer's protocol (GE Healthcare Life Sciences). Genomic DNA was extracted using the Qiagen DNeasy blood and tissue kit according to the manufacturer's protocol. Biochemical measurement of methylcytosine was performed using the Imprint® Methylated DNA Quantification Kit (Sigma Aldrich) after normalization of genomic DNA (gDNA) concentration. Linear correlation analysis for Hcy, age and methylcytosine was undertaken.
Methyl-CpG capture assay
Enrichment of methyl-CpG containing DNA was performed with the Methylminer DNA Enrichment Kit (Life Technologies) as described previously [11] . Briefly, 1 μg of purified genomic DNA was fragmented by sonication (Diagenode Bioruptor), and verified with capillary electrophoresis analysis on MultiNA instrument with DNA-2500 kit (Shimadzu). Then 500 ng of sheared DNA was incubated for 1hr with magnetic beads bound to methyl-CpG binding domain of human MBD2 protein. Unmethylated DNA was depleted by three washes with 160 mM NaCl solution, and bound methylated DNA was eluted with 600 mM NaCl solution. Enriched DNA was quantified with Qubit fluorometer (Invitrogen). A sample of 1 μg human DNA (K562 cell line) containing a spike-in of synthetic methylated and unmethylated oligonucleotides was processed in parallel and the ratio of methylated to unmethylated oligonucleotide was determined with qPCR to verify enrichment of methylated DNA.
Next generation sequencing of methylenriched DNA
Library preparation from 5 ng of methyl-enriched DNA was performed with the NEBNext DNA Library Preparation Kit for Illumina (New England Biolabs). To analyze the difference between MBD-seq and DNA-Seq, 5 ng of fragmented genomic DNA without methylation enrichment underwent library preparation in parallel. Library DNA was quantified with MultiNA capillary electrophoresis instrument with DNA-500 kit. Cluster generation was done using library DNA at a concentration of 10 pM on Cluster Station (Illumina). Sequencing by synthesis was performed on Genome Analyzer IIx (Illumina) for 36 cycles using RTAv1.8 base calling software.
Repeat sequence analysis
Repeat DNA content was determined by submitting 1 million randomly selected sequence reads to RepeatMasker (http://repeatmasker.org) using repeat libraries specifically derived from human genomic sequence. Repeat content of MBD-seq datasets were compared to input datasets derived from PBMCs of two male and two female subjects.
Genome wide screen for differential methylation
Reads derived from MBD-enriched samples were aligned to the human genome Hg19 build using BWA [12] with the default parameters. Only reads with a mapping quality score ≥20 were considered in downstream analysis. Gene methylation was initially analysed by counting read coverage in genome bins of 1 Mbp and 1 kbp with BedTools [13] . Secondly reads were counted in gene bodies, including 2 kbp upstream of transcriptional start site. Gene body coordinates were extracted from the Gencode v14 GTF annotation file (www.gencodegenes. org/releases/14.html). Differential methylation analysis was undertaken after library size normalization with the edgeR statistical package using a general linear model (GLM) feature using a significance threshold of 0.05 after false-discovery rate (FDR) correction using the Benjamini Hochberg method [14] . GLM analysis with edgeR was used to correct for covariates one at a time. Genome ideogram was plotted using Circos software [15] .
Intersection of differential methylation with genomic features
Areas of differential methylation were analyzed for nucleotide composition and CpG content using BedTools nuc tool. The methylome-wide background was used for comparison, defined as all regions exceeding the threshold level of detection (10 or more reads per sample on average). DMRs were intersected with various genomic features to understand the context of methylation changes. CpG islands (CGI) defined previously [16] were downloaded from UCSC table browser for the hg19 build (http://genome.ucsc.edu/cgi-bin/hgTables). CpG shores (CGS) were defined as regions located 1 bp to 2 kbp away from CGIs [17] . DNase hypersensitivity regions include proximal and distal sites cataloged by the ENCODE consortium, and many are hypothesized to harbor active cis-elements [18] . Promoters were defined as regions spanning 2 kbp upstream and downstream of a TSS, according to GENCODE v14. Introns, exons and untranslated regions (UTRs) according to the GENCODE v14 annotation set were downloaded from the UCSC table browser. Promoter regions were mined from the GENCODE v14 GTF annotation with BedTools. Intergenic regions were determined by finding the complement of annotated genes with BedTools.
Intersection of differentially methylated genes with candidate genome wide association study genes
Differentially methylated genes were intersected with genes previously identified in GWAS for stroke, CVD, hypertension, dyslipidemia and Hcy. To generate methylation profiles across genes, MACS [19] was used to generate wiggle files with a resolution of 10 bp. Read coverage were overlaid upon genomic features by uploading wiggle files to UCSC genome browser (http:// genome.ucsc.edu/cgi-bin/hgTracks).
Results
Analysis of cohort characteristics and MBD-seq data
Gender, age, Hcy titer and global DNA methylation levels of subjects were recorded. MBD-seq was performed on peripheral blood mononuclear cells (details included in the Supplemental Materials and Methods). Data metrics include the number of sequence reads, GC content, mean base call quality, proportion of reads aligned to the genome at varying alignment quality thresholds (mapQ) and repeat-masked sequence as well as reads originating from Alu and LINE-1 elements (Table 1) . Sequence base quality was high for all samples and was independent of the proportion of ambiguously mapped reads (Supplementary Figure 1) . Correlation analysis demonstrated a significant association between age and reduced 5mC when male and female data were combined (r=-0.8, p=0.01, Table 2 ). We observed an association between GC content and Hcy concentration in males (r=0.99, p=0.007), but not in females (r=-0.56, p=0.41). GC content was strongly correlated with Alu content (r=0.99, p=2.6E-6) and the proportion of LINE-1 DNA was inversely correlated with Alu content (r=-0.95, p=3.2E-4).
Differential methylation in the pilot cohort
We scanned for differentially methylated regions (DMRs) associated with clinical variables such as gender, age, Hcy titer and hypertensive status. To do this, genomic bin sizes of 1 Mbp and 1 kbp were used. We focused on identifying regions associated with a test variable after adjustment for covariates using general linear model (GLM) statistics (FDR adj p-val ≤ 0.05). With respect to gender we observed In order to define genomic features that undergo differential methylation, we analyzed DMRs for GC and CpG dinucleotide content. Firstly, hypermethylated regions in males with elevated Hcy has 390% higher CpG content whereas hypo-methylated genes exhibited a 34% are plotted against Alu content in a genomic ideogram, showing changes in methylation content as well as subtelomeric regions (Figure 1 ). At the 1-kbp interval size, we observed 410 1-kbp DMRs associated with hypertensive status, while 482 DMRs were inversely associated with hypertensive status and mapped to 225 and 355 genes, Table 1 . Analysis of cohort characteristics and MBD-seq data metrics. Characteristics for each of the eight individuals in the pilot study. HS refers to hypertensive status, N refers to normotensive, H refers to hypertensive, Hcy refers to total plasma homocysteine, 5mC Absorbance refers to the measurement of methylcytosine after normalisation of total genomic DNA. Total reads refers to the number of MBD-seq reads generated for that sample. %Aligned refers to the proportion of reads aligned to the human genome irrespective of mapQ value. %mapQ ≥20 refers to the proportion of reads which aligned to the human genome with a map quality ≥20. %Repeatmasked, %Alu and %LINE-1 refers to the proportion of MBD-seq bases which were identified as repetitive elements, Alu elements and LINE-1 elements by Repeatmasker. *values are an average of four samples +/-one standard deviation. Figure  2A) . In hypertensive females, hypermethylated regions showed a 31% lower CpG content whereas hypomethylated regions showed 860% higher CpG content compared to the background. These regions show variability in %GC content ( Figure 2B ). Next, DMR coordinates were intersected with genomic features such as promoters, CpG islands (CGI), CpG shores (CGS), exons, and DNase hypersensitivity sites (DNase HS). In males with HHcy, approximately 20% of hypermethylation events occurred at CGIs which was almost 9 fold higher when compared to methylation background ( Figure 2C ). Hypermethylation was also more likely to occur at CGS, DNase HS, promoters and gene bodies including exons, introns and UTRs. Conversely, hypomethylation events were more broadly distributed. In hypertensive females, approximately 64% of hypomethylation events overlapped with CGIs ( Figure  2D ).
Patient
Genes associated with heart disease, stroke and hypertension
To assess whether polymorphic genes previously identified by GWAS intersect DMRs, we screened gene sequences implicated in CVD, stroke, hypertension and dyslipidemia (Table 5 ). In the male group, elevated Hcy was associated with hypomethylation of NOX4 and SYT9, whereas we observed hypermethylation of CBS, DPEP and MTHFR genes. In the female group, demethylation of CELSR1 and LDLR alleles were associated with hypertension. To visualise 5mC variability read count profiles were generated for CBS and LDLR ( Figure 2E ).
Discussion
To our knowledge, this is the first report correlating genome-wide methylation profiling with plasma homocysteine levels and hypertension in ischemic stroke patients. This approach provides a map of DNA methylation sites. Whilst we appreciate the study is limited in sample size, our approach identified several original observations. Firstly, in the male group, we observe correlations between MBD-seq data metrics and Hcy titer that suggest interactions between the remethylation pathway and DNA methylation. For example, enrichment of Alu repeat elements was directly proportional to plasma Hcy titer. Males with HHcy show hypomethylation at sites of low CpG content and predominantly intergenic DNA. These results are consistent with the idea that CpG-poor intergenic DNA are sensitive to demethylation in HHcy. In contrast, subtelomeric DNA considered rich in genes and Alu repeat elements were protected from hypomethylation. In the female group, the correlation between Alu content and Hcy remains unclear.
Our methylome wide screen shows that (i) gender differences were largely limited to sex chromosomes, (ii) age correlated with relatively little variation in genomic Table 4 . Genome-wide scan for differential methylation correlating with Hcy and hypertension. GLM analysis was performed for genome bins of 1 Mbp and 1 kbp. Male and female groups were analysed separately. GLM analyses were performed adjusting for covariates one at a time. Regions with FDR adj p-val ≤ 0.05 were considered significant. The 1 kbp bins were annotated with a gene name if they located within a gene body or 2 kbp upstream of the transcriptional start site defined by GENCODE genes version 14. Brought to you by | Monash University -Caul Authenticated Download Date | 3/30/17 6:27 AM methylation in this cohort, (iii) methylation changes in the male group correlate with Hcy, and (iv) methylation changes observed in the female group correlate with hypertensive status. Genes associated with cardiovascular disease with variable DNA methylation include APOE, LDLR, F2 and F7; as well as key genes involved in the remethylation pathway such as CBS and MTHFR. While our methylome-wide study comprising eight stroke patients uncovered statistically significant relationships with homocysteine and hypertension, it is unknown how many of these loci would be replicable in larger patient cohorts. Moreover, we recognize that observed changes in 5mC could reflect differences in blood cell composition [20] . Previous reports describe a correlation between white blood cell count and elevated Hcy along with other CVD risk factors such as systolic blood pressure [21, 22] . More specifically, the neutrophil to lymphocyte ratio correlates with risk of cardiovascular events [23] .
Hcy
While further work is required to resolve the negative health impacts of elevated Hcy, this study demonstrates the feasibility of methylome profiling using MBD-seq identifying variable methylation at genes implicated with vascular disease. These findings will assist in the design of larger methylome association studies related to HHcy and CVD.
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Protocol for MethylMiner methylated DNA enrichment and library preparation for Illumina 1 DNA sonication optimisation Note: Sonicators vary widely in efficiency and sonication conditions need to be optimised and we suggest the following as a guide: 1.1 Diagenode Bioruptor sonicator with external water bath cooling module (4°C) and peristaltic pump to circulate cool water all kept in a cool-room (4°C) 1.2 Use a commercially available source of DNA for sonication optimisation (ie, salmon sperm DNA). 1.3 Maintain all variables constant execept the duration of sonication. This includes the power setting (high power), sample diluent (TE buffer), number of microfuge tubes in the sonicator at any time (3), volume of liquid in each microfuge tube (100 μL) and the interval (30s on/30s off), concentration of DNA (10 ng/uL, total DNA amount: 1 μg) 1.4 Sonicate optimisation samples for 5, 10, 15, 20 and 25 mins using the above conditions. Every 5 mins, briefly spin down the liquid in the tubes and monitor sonicator water temperature does not exceed 20°C. 1.5 Analyse the sonication patterns of these DNA samples using Shimadzu MultiNA DNA 2500 Kit or other suitable 2 DNA sonication samples of interest 2.1 Ensure the quality and quantity of DNA is sufficient. We suggest 0.5% agarose gel electrophoresis for quality analysis and Qubit® fluorometric quantitation (Life Technologies) to accurately determine dsDNA concentration. 2.2 Aliquot 1 μg of purified genomic DNA into 1.5 mL microfuge tube and make up to 100 μL in water or TE buffer. 2.3 Sonicate for the optimised duration (determined in step 1.4) using the conditions specified in . 2.4 Verify uniform sonication of sample DNA with MultiNA bioanalyzer or similar. The concentration of fragmented DNA determined here should be recorded. Keep a 10 μL aliquot labelled "input DNA".
3 Preparing the MBD-coupled beads. Note that the beads should be prepared in a single volume sufficient for all samples rather than individually. We recommend including a control sample consisting of K562 or HeLa DNA to each batch of samples to evaluate the batch-tobatch variability of enrichment of spike-in methylated and unmethylated DNA. 3.1 Prepare 1X Bind/Wash Buffer. For each sample to be processed, prepare 1.8 mL of 1X Bind/Wash Buffer as follows. 7 DNA purification is performed using Qiagen MinElute columns (MinElute Gel Extraction Kit) for the noncaptured DNA supernatant fraction, the non-captured DNA wash fraction and MBD-captured fraction. 7.1 Add 5 volumes of Qiagen PB Buffer to 1 volume of DNA solution, mix thoroughly and add up to 700 μL of this mixture to a MinElute column. Spin for 1 min in microfuge at top speed and discard the flow-through. Repeat as necessary to process entire sample volume. 7.2 Add 700 μL of Qiagen PE wash buffer to the column, spin for 1 min in microfuge at top speed and discard the flow-through. 7.3 Replace the spin column in the collection tube and spin for 1 min in microfuge at top speed to remove remaining liquid. Discard the collection tube and place in a clean microfuge tube. 7.4 Air dry the tube for 5 mins then add 20 μL of Qiagen Elution Buffer (EB) directly to the spin column membrane. Spin for 1 min in microfuge at top speed to elute DNA. 9.6 Clean-up of PCR reactions is performed at a post-PCR bench using the recommended AMPure XP bead protocol and elution in 30 μL of Tris-HCl buffer. 9.7 Analyse 6 μL of library on MultiNA bioanalyser with DNA2500 kit to determine library concentration. 9.8 Normalise library concentration to 10 pM by diluting libraries with appropriate volume of Tris-HCl buffer and run normalised libraries on bioanalyzer to more accurately determine library conncentration. Use these concentrations to pool the libraries in equimolar ratios. This step greatly inproves balanced library representation. 9.9 Pooled libraries are now ready for cluster generation on the system-of-choice.
